Clinical Trials Logo

Filter by:
NCT ID: NCT05434325 Recruiting - Kidney Diseases Clinical Trials

TESTING -ON Post-Trial ObservatioNal Cohort Study

TESTING-ON
Start date: December 7, 2022
Phase:
Study type: Observational

The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).

NCT ID: NCT05427578 Recruiting - Depression Clinical Trials

Brain Markers of Depression Vulnerability: the Case of Prefrontal Haemodynamic Response

Start date: August 1, 2021
Phase:
Study type: Observational

Functional near infrared spectroscopy (fNIRS) offers a cheap and reliable tool to investigate prefrontal brain activation in the healthy and diseased human brain. As such, fNIRS bears great potential as a diagnostic tool for clinical practice. Research indicates that fNIRS, together with a relatively simple task to activate the prefrontal cortex, the so-called verbal fluency task (VFT), elucidates prefrontal dysfunction in major depressive disorder (MDD). This finding can potentially serve as an imaging marker for disease pathology, even when depressive symptoms are absent. Indeed, recent research also suggests prefrontal dysfunction in fully remitted MDD (rMDD). Prefrontal haemodynamic responses may therefore serve as a trait marker for MDD vulnerability. This study aims to investigate the haemodynamic response in rMDD, healthy participants with increased MDD risk (HCr; having a 1st-degree relative with MDD), and low-risk healthy participants (HCnr; having no 1st-degree relatives with MDD) using fNIRS. The investigators hypothesize lower prefrontal reactivity in HCr compared to HCnr, and lowest prefrontal reactivity in rMDD compared to HCnr. This study has the potential to elucidate the neuronal underpinnings of depression vulnerability in the absence of symptoms that are sometimes considered a confounding factor when it comes to studying the biological encoding of depression.

NCT ID: NCT05427071 Recruiting - Chemotherapy Effect Clinical Trials

Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy

MaCTAD
Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive breast cancer following neoadjuvant therapy

NCT ID: NCT05425940 Recruiting - Colorectal Cancer Clinical Trials

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

STELLAR-303
Start date: September 7, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

NCT ID: NCT05424952 Recruiting - Clinical trials for Vaccination Hesitancy

The Effectiveness of Conversational AI Service (Chatbot) Utilization on Vaccine Confidence

Start date: February 11, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to develop and evaluate a conversational AI service (chatbot) on social media platforms to obtain accurate and up-to-date vaccine information, and assess the impact of chatbot usage on users' vaccine confidence and acceptance in Hong Kong, Singapore, and Thailand.

NCT ID: NCT05422729 Recruiting - Clinical trials for Heart Disease Risk Factors

mHealth-supported Coach

Start date: September 5, 2022
Phase: N/A
Study type: Interventional

A randomised controlled trial to evaluate the effects of a personalised mHealth-supported coach programme in the middle-aged group with stroke risk.

NCT ID: NCT05422274 Recruiting - ADHD Clinical Trials

Effect of Transcranial Pulse Stimulation on ADHD

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This is the first nationwide study using Transcranial Pulse Stimulation to evaluate its efficacy and safety on 30 young adolescents with ADHD. Six verum/ shamTPS sessions will be delivered to all subjects on a 1: 1 ratio, balanced by gender and age. Attention deficit, hyperactivity, impulsivity, and oppositional defiance will be the primary outcome. Secondary outcomes include ADHD severity, frequency of inattention, hyperactivity, impulsivity, executive function and neural connectivity changes via neuroimaging. Results emerging from this study will generate new knowledge to ascertain whether TPS can be used as a top-on treatment in ADHD.

NCT ID: NCT05419375 Recruiting - Solid Tumors Clinical Trials

Screening Study for Participants With Malignant Tumors

Start date: July 22, 2022
Phase: Phase 2
Study type: Interventional

The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.

NCT ID: NCT05418569 Recruiting - Clinical trials for Type1 Diabetes Mellitus

Chinese Smartphone App for 6-18 Years With T1DM - RCT

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Moving into the era of electronic communication, it changes the way we shall engage our children and adolescents. According to data of the Census and Statistics Department of Hong Kong releases in 2019, more than 80% and up to 99.4% of those aged 10-14 years, and aged 15-24 years respectively had a mobile phone device. A recent survey carried by Kebede et al. (2019) had shown that using diabetes apps was positively associated with self-care behavior in type 1 and type 2 diabetes mellitus (DM). A systematic review carried in Spain by Quevedo Rodríguez et al. (2018) had found most of the available smartphone apps lacked quality certification and very few provide scientific references on their content. In Hong Kong, there is currently no Chinese smartphone application targeting for the pediatric type 1 population, therefore, most of the education is based on face-to-face or telephone communication with the diabetic nurse and endocrinologists in limited encounters. For families or patients with limited command of English language, apart from one adult oriented DM information smartphone application, the chance of having on-hand mobile device support is truly limited. In light of this context, we shall first design an evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM and then evaluate its effectiveness in improving management of type 1 DM in a robust manner. The main research question for this project is whether a self-help smartphone application in local Chinese language, tailored to include local clinical practice, culture and food spectrum, can improve diabetes control and psychological wellbeing in patients with type 1 diabetes mellitus aged 6-18 years. Eligible participants will be randomized to either using the smartphone application (on top of standard diabetic care) or continue standard diabetic care. The study aims to compare the difference between the two groups for their diabetic control and the psychological wellbeing.

NCT ID: NCT05417932 Recruiting - Clinical trials for Hepatocellular Carcinoma Recurrent

A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

TCR-T
Start date: October 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma